Latest News - Boston Scientific
Top Corporates Hub
Boston Scientific
How Investors May Respond To Boston Scientific (BSX) Strong Q1 Beat But Cut Guidance On Watchman Growth
05.06.2026 17:11
In late April 2026, Boston Scientific reported quarterly revenue of US$5.20 billion, up 11.6% year on year and ahead of expectations, but cut near-term and full-year guidance amid intensifying cardiac market competition and slowing growth in its Watchman stroke-prevention device. This combination of strong recent performance and a more cautious outlook, reinforced by downgrades from firms like Wolfe Research, has sharpened investor focus on how resilient Boston Scientific’s growth drivers...
How A Quiet Reset Is Shaping The Boston Scientific (BSX) Investment Story
02.06.2026 12:05
Boston Scientific enters this update cycle with no changes to its current price target, leaving expectations exactly where analysts previously set them. With no new analyst commentary on the stock, the story is less about fresh opinions and more about how existing views are holding steady for now. Ahead, you will see how to track this kind of quiet reset and what it can signal as the narrative around Boston Scientific continues to evolve. Stay updated as the Fair Value for Boston Scientific...
FRACTURE IDE Success Adds Clinical Support To Boston Scientific Valuation Case
02.06.2026 11:14
Boston Scientific (NYSE:BSX) reported strong positive results from its pivotal FRACTURE IDE trial for the SEISMIQ 4CE coronary intravascular lithotripsy catheter. The trial assessed safety and effectiveness of SEISMIQ 4CE in treating severely calcified coronary artery disease, a complex area of interventional cardiology. This clinical milestone relates to Boston Scientific's coronary portfolio and has not been the focus of recent coverage that centered on Watchman and product...
Peripheral Vascular Devices Market by Type, End User - Global Forecast to 2031
02.06.2026 08:49
The global peripheral vascular devices market is set to reach USD 13.22 billion by 2031, growing at a CAGR of 5.7% from USD 10.02 billion in 2026. This growth is fueled by the increasing prevalence of vascular disorders like PAD, linked to aging, diabetes, obesity, and smoking. Innovations in minimally invasive devices, such as drug-coated balloons and next-gen stents, are boosting clinical outcomes, while ambulatory surgical centers are driving procedural shifts. The Asia Pacific region, led by
Why Did BSX, LI, ROL Stocks Fall To 52-Week Lows On Friday?
01.06.2026 03:01
Analyst downgrades, weak outlooks, and management changes added pressure.
Why Did BSX, LI, ROL Stocks Fall To 52-Week Lows On Friday?
01.06.2026 03:01
Analyst downgrades, weak outlooks, and management changes added pressure.
Boston Scientific Corp (NYSE:BSX): A Decent Value Play with Strong Fundamentals and an Attractive Valuation
30.05.2026 09:40
Discover Boston Scientific (BSX) as a 'Decent Value' stock: strong profitability, solid growth, and a low P/E ratio, offering a margin of safety for value investors.
Boston Scientific (BSX) Valuation Reset After Watchman Growth Concerns And Intensifying Competition
30.05.2026 08:04
Boston Scientific (BSX) stock has been under pressure after management flagged slowing growth in its Watchman heart implant business, a key contributor to earnings. The company reaffirmed full year guidance and is facing fresh competition in left atrial appendage closure. See our latest analysis for Boston Scientific. The sharp reset in expectations for Watchman growth has coincided with a steep share price selloff, with the stock down 37.1% over three months and the 1 year total shareholder...
Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
28.05.2026 15:05
Investing.com -- Wells Fargo has downgraded Boston Scientific to “Equal Weight” from “Overweight,” citing growing uncertainty around the medical device maker’s two key growth drivers — its electrophysiology (EP) business and the Watchman heart implant franchise.
Why Did BSX, LI, BJ Stocks Hit 52-Week Lows Today?
28.05.2026 03:22
Investors have recently become less willing to tolerate compressed margins tied to rising costs and slowing demand.
Boston Scientific stock tumbles 6% after guidance cut
27.05.2026 13:46
Investing.com -- Boston Scientific Corp (NYSE:BSX) fell over 6% Wednesday after management lowered its full-year guidance during a presentation at Bernstein.
Boston Scientific Recalls Test Cardiac Device Quality And Investor Confidence
26.05.2026 06:07
Boston Scientific (NYSE:BSX) has initiated two voluntary recalls of its LUX-Dx II arrhythmia detector and alarm devices. The recalls follow FDA enforcement reports citing failures in data collection and monitoring of critical cardiac events for certain patients. Issues include discrepancies in device programming interfaces that affect reliability of arrhythmia monitoring and treatment decisions. The recalls are ongoing and affect patients and clinicians in multiple regions, including the US...
Why Is Boston Scientific (BSX) Down 13% Since Last Earnings Report?
22.05.2026 15:30
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ISRG's SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
21.05.2026 12:54
ISRG's SP platform sees Q1 2026 procedures jump 68%, with new approvals and tools raising a key question: TAM expansion or procedure shift?
Boston Scientific Corp (NYSE:BSX) GARP Growth at a Reasonable Price Meets Strong Fundamentals
21.05.2026 09:40
Boston Scientific (BSX) fits a GARP strategy with solid growth, a P/E of 18.28, high profitability, and strong health ratings—ideal for balanced investors.
Jim Cramer on Globus Medical: “There Is Not a Lot of Money to Be Made in This One”
20.05.2026 18:05
Globus Medical, Inc. (NYSE:GMED) was among the stocks Jim Cramer looked at as he explained the need for a tame bond market for the stock market to go higher. A caller asked for Cramer’s thoughts on the company, and he remarked: Okay, this group in particular, the medical device group, is hated in this market. […]
Boston Scientific Trial Success Adds Weight To SEISMIQ 4CE And BSX Valuation
20.05.2026 17:06
Boston Scientific (NYSE:BSX) reported positive pivotal trial results for its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter. The FRACTURE trial met all primary safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The company plans to use these data to support a regulatory submission for SEISMIQ 4CE. Boston Scientific is a major player in interventional cardiology, with products focused on treating complex coronary and structural heart...
Boston Scientific Corporation (BSX) Fell Due to Weak Results
20.05.2026 13:19
TCW Funds, an investment management firm, published its first-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter is available to download here. The first quarter was marked by volatility in equity markets, driven by geopolitical tensions, concerns about the private credit sector, a government shutdown, and ongoing […]
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target
20.05.2026 11:23
With a 5-year average revenue growth rate of 13.52%, Boston Scientific Corporation (NASDAQ:BSX) is included among the 11 Best Long Term US Stocks to Buy Right Now. On May 19, Baird lowered its price recommendation on Boston Scientific Corporation (NASDAQ:BSX) to $75 from $78. It reiterated an Outperform rating on the shares. The firm updated its model […]